logo
Plus   Neg
Share
Email

Aurobindo Pharma Gets Final Approvals For Quetiapine Fumarate Tablets

Manufacturer of generic pharmaceuticals and active pharmaceutical ingredients Aurobindo Pharma Ltd. announced that the company had obtained final approvals from the US Food & Drug Administration or US FDA to market Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg.

Quetiapine Fumarate tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mgare the generic equivalent of AstraZeneca LP's Seroquel tablets 25mg, 50mg, 100mg, 150mg, 200mg, 300mg and 400mg. These tablets are indicated for the treatment of serious psychotic disorders such as Schizophrenia and Bipolar Disorder and fall under the Neurological (CNS) therapeutic category.

The company said the product had been approved out of Unit III facility in Hyderabad, India.

Aurobindo now has a total of 147 ANDA approvals (118 final approvals and 29 tentative approvals)from US FDA.

AT the BSE, Aurobindo Pharma shares are currently trading at Rs.116.55, up 1.66 percent from the previous close.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
Tens of thousands of casino workers in Las Vegas voted Tuesday to authorize a city-wide strike anytime after June 1 if labor contract agreements are not reached before they expire at the end of May. This would be the first strike in more than three decades in Las Vegas and could cripple the city's famed hospitality industry. Ten former and current employees of McDonald's Corp. have filed sexual harassment complaints with the federal government against the fast food giant. The women filed the complaints with the U.S. Equal Employment Opportunity Commission or EEOC and are receiving support from Fight for $15, which is organizing the effort. The TIME's UP Legal Defense Fund is covering legal fees for the women. A bill rolling back financial regulations implemented following the 2008 financial crisis is headed to President Donald Trump's desk for his signature after being approved by the House on Tuesday. The House voted 258 to 159 in favor of the Economic Growth, Regulatory Relief, and Consumer Protection...
Follow RTT